Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bay 59-7939 after total hip replacement
ACTRN12606000069550Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Bayer. Primary endpoints: Composite primary efficacy endpoint, Any deep vein thrombosis and 2 more. Started Feb 2006; status: completed.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ACTRN12606000069550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000069550.